Dicerna Pharmaceuticals Inc. (DRNA)

13.65
NASDAQ : Health Technology
Prev Close 13.08
Day Low/High 13.04 / 13.79
52 Wk Low/High 2.69 / 15.80
Avg Volume 548.20K
Exchange NASDAQ
Shares Outstanding 52.82M
Market Cap 690.91M
EPS -3.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Dicerna To Present At The Jefferies 2018 Global Healthcare Conference

Dicerna To Present At The Jefferies 2018 Global Healthcare Conference

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M.

DRNA Crosses Above Average Analyst Target

In recent trading, shares of Dicerna Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $13.60, changing hands for $13.77/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Dicerna Reports First Quarter 2018 Financial And Operating Results And Provides Corporate Update

Dicerna Reports First Quarter 2018 Financial And Operating Results And Provides Corporate Update

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the first quarter ended March 31, 2018.

Dicerna To Report First Quarter 2018 Financial Results And Host Conference Call On May 14, 2018

Dicerna To Report First Quarter 2018 Financial Results And Host Conference Call On May 14, 2018

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2018 financial results after market close on Monday,...

First Week Of DRNA June 15th Options Trading

Investors in Dicerna Pharmaceuticals Inc saw new options become available this week, for the June 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DRNA options chain for the new June 15th contracts and identified one put and one call contract of particular interest.

Dicerna Pharmaceuticals Announces Settlement Of All Litigation With Alnylam

Dicerna Pharmaceuticals Announces Settlement Of All Litigation With Alnylam

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the company has resolved all litigation with Alnylam Pharmaceuticals, Inc.

Dicerna To Present At The H.C. Wainwright Global Life Sciences Conference

Dicerna To Present At The H.C. Wainwright Global Life Sciences Conference

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M.

Dicerna To Present At The B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium

Dicerna To Present At The B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M.

Dicerna Reports Fourth Quarter And Year End 2017 Financial And Operating Results And Provides Corporate Update

Dicerna Reports Fourth Quarter And Year End 2017 Financial And Operating Results And Provides Corporate Update

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the fourth quarter and...

Dicerna To Present At The Cowen And Company 38th Annual Health Care Conference

Dicerna To Present At The Cowen And Company 38th Annual Health Care Conference

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M.

Dicerna To Report Fourth Quarter And Full Year 2017 Financial Results And Host Conference Call On March 8, 2018

Dicerna To Report Fourth Quarter And Full Year 2017 Financial Results And Host Conference Call On March 8, 2018

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its fourth quarter and full year...

The DRNA Paradox: Analysts Bullish But Forecast -9.62% Fall

The DRNA Paradox: Analysts Bullish But Forecast -9.62% Fall

Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Dicerna Pharmaceuticals Inc . The average 12-month price target for DRNA — averaging the work of 5 analysts — reveals an average price target of $10.80/share.

Choppy Market Action This Morning

Choppy Market Action This Morning

The good news is that there is some stock picking that is working well.

Dicerna To Participate In Upcoming Investor Conferences

Dicerna To Participate In Upcoming Investor Conferences

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M.

Stock Market Momentum Continues, Beat Goes On

Stock Market Momentum Continues, Beat Goes On

I don't want to spend too much time focusing on market timing as it is much more profitable to focus on stock picking.

DRNA Crosses Above Average Analyst Target

DRNA Crosses Above Average Analyst Target

In recent trading, shares of Dicerna Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $9.00, changing hands for $9.57/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Dicerna To Present At Noble Capital Markets' NobleCon14

Dicerna To Present At Noble Capital Markets' NobleCon14

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M.

Dicerna Announces Pricing Of Follow-On Public Offering Of Common Stock

Dicerna Announces Pricing Of Follow-On Public Offering Of Common Stock

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) ("Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced today the pricing of its underwritten registered public...

DRNA Crosses Above Average Analyst Target

DRNA Crosses Above Average Analyst Target

In recent trading, shares of Dicerna Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $7.75, changing hands for $7.84/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Dicerna Announces Proposed Public Offering Of Common Stock

Dicerna Announces Proposed Public Offering Of Common Stock

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) ("Dicerna" or the "Company"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced today the commencement of a proposed...

Dicerna Announces First Human Dosed In Phase 1 Clinical Trial Of DCR-PHXC For Treatment Of All Forms Of Primary Hyperoxaluria

Dicerna Announces First Human Dosed In Phase 1 Clinical Trial Of DCR-PHXC For Treatment Of All Forms Of Primary Hyperoxaluria

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced the dosing of the first human in DCR-PHXC-101, a Phase 1 clinical trial of DCR-PHXC, the...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ANF, CWCO, DOOR, GCP, OSN, PLT, SJT, TRC Downgrades: FNGN, OPNT, ZBH Initiations: CSTR, DRNA, MPO, MRT Read on to get TheStreet Quant Ratings' detailed report:

Dicerna To Present At The Evercore ISI Biopharma Catalyst/Deep Dive Conference

Dicerna To Present At The Evercore ISI Biopharma Catalyst/Deep Dive Conference

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M.

Dicerna To Present At The Stifel 2017 Healthcare Conference

Dicerna To Present At The Stifel 2017 Healthcare Conference

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M.

Dicerna Pharmaceuticals Reaches Analyst Target Price

Dicerna Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Dicerna Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $5.75, changing hands for $7.23/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Dicerna Reports Third Quarter 2017 Financial And Operating Results And Provides Corporate Update

Dicerna Reports Third Quarter 2017 Financial And Operating Results And Provides Corporate Update

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the third quarter ended September 30,...

Boehringer Ingelheim And Dicerna Announce Collaboration To Develop Novel Treatments For Chronic Liver Diseases Including Nonalcoholic Steatohepatitis (NASH)

Boehringer Ingelheim And Dicerna Announce Collaboration To Develop Novel Treatments For Chronic Liver Diseases Including Nonalcoholic Steatohepatitis (NASH)

Boehringer Ingelheim and Dicerna Pharmaceuticals (NASDAQ:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced a research collaboration and license agreement to discover and...

Dicerna To Report Third Quarter 2017 Financial Results And Host Conference Call On November 2, 2017

Dicerna To Report Third Quarter 2017 Financial Results And Host Conference Call On November 2, 2017

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2017 financial results...

TheStreet Quant Rating: D (Sell)